Biohaven LtdNYSE BHVN Stock Report

Biohaven Ltd. operates as a biopharmaceutical company that focuses on neurological and neuropsychiatric diseases. The company is headquartered in New Haven, Connecticut. The company went IPO on 2022-09-23. The firm combines a deep understanding of neuroscience, immunology, disease-related biology, advanced chemistry, and expertise in global clinical trials to advance novel therapies for patients. The firm is engaged in delivering new drug approvals for products for diseases such as migraine and schizophrenia, and its research programs, built on a deep understanding of disease-related biology and neuropharmacology, are advancing novel therapies with indications in spinocerebellar ataxia (SCA), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), epilepsy, depression, obsessive-compulsive disorder (OCD) and neuropathic pain. Its Neuroinnovation portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7 ion channels (Kv7), glutamate receptors, myeloperoxidase (MPO), myostatin, and transient receptor potential (TRP) channels.